Novo Nordisk (NOVO) 44th Annual J.P. Morgan Healthcare Conference summary

Strategic focus and business direction

• Renewed focus on diabetes and obesity, with adjacent indications only pursued if linked to these core areas.

• Innovation-driven strategy targets leadership in obesity, diabetes, and related comorbidities.

• Rare disease business continues as a distinct, biotech-like unit.

• Addressing a large unmet need, with only a small fraction of the 2 billion affected individuals currently treated; over 550 million live with diabetes and more than 900 million with obesity globally.

• Related comorbidities include over 500 million with cardiovascular disease, 800 million with chronic kidney disease, and 250 million with MASH.

Commercial execution and market expansion

• Plans to launch higher dose Wegovy (7.2 mg) and Wegovy pill in the US to enhance competitive positioning.

• Direct-to-patient and consumer channels prioritized, with partnerships including Ro, LifeMD, Amazon, WeightWatchers, and Costco.

• Expansion of the obesity market targeted, especially through oral formulations like the Wegovy pill.

• Focus on mastering cash and e-health channels in the U.S. due to insurance coverage limitations.

• Emphasis on expanding access to the 85 million U.S. patients not currently using injectables.

Product innovation and competitive landscape

• Rybelsus (oral semaglutide) offers weight loss efficacy comparable to injectables, with lower discontinuation rates due to tolerability.

• Wegovy pill positioned as a market leader, with cardiovascular benefits included in its label.

• Oral formulations expected to broaden the market rather than cannibalize injectables, appealing to patients averse to injections or cold chain requirements.

• Higher dose semaglutide (7.2 mg) shown to achieve up to 20% weight loss, challenging perceptions of generational drug improvements.

• Price reductions expected to drive volume growth, but with short-term financial pain before broader market adoption.